An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19Florence Ader, Marion Noret, Aline Dechanet et al.|Clinical Microbiology and Infection|2021Cited by 107
Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trialFlorence Ader, Marion Noret, Nathan Peiffer‐Smadja et al.|medRxiv|2021Cited by 15
Risk Factors for Anal Continence Impairment Following a Second Delivery after a First Traumatic Delivery: A Prospective Cohort StudyGabriel Marcellier, Laurent Abramowitz, Axelle Dupont et al.|Journal of Clinical Medicine|2023Cited by 4
An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trialFlorence Ader, Marion Noret, Nathan Peiffer‐Smadja et al.|medRxiv|2022Cited by 1